Clinical electrophysiological studies(EPS) were done in seven patients with chronic recurrent sustained ventricular tachycardia(VT) in an attempt to delineate the reproducibility and to select the effective antiarrhythmic drugs for the prevention of the recurrence of VT. We could induce and terminate the sustained VT, and could select the effective antiarrhythmic drugs in all patient in the cardiac catheterization laboratory with EPS. With these effective antiarrhythmic drugs VT did not recur for the follow up period of 15 to 20 months. In view of the serious nature of the VT and the demonstrated benefits of EPS, we could conclude that patients with chronic recurrent sustained VT should undergo EPS.
Anti-Arrhythmia Agents ; Cardiac Catheterization ; Cardiac Catheters ; Follow-Up Studies ; Humans ; Recurrence ; Tachycardia, Ventricular*

The antihypertensive action of Lasix(R) retard 30 was evaluated in 20 cases of essential hypertension on an outpatient basis. The following results were obtained. 1. The patient population comprised 11 males and 9 females, aged 32 to 67 years, with mild to moderate essential hypertension. mean age was 50 years, with 75% between 40 and 59 years of age. 2. The daily effective doses ranged from 1 to 3 capsules with an average of 1.7 capsules. The total duration of medication ranged from 4 to 12 weeks with an average of 6.5 weeks. 3. In 60% of the cases, good or fair control of blood pressure was resulted. Most of the poor results were in the cases of moderate hypertension, but the results could be improved with continuous treatment or combination with other antihypertensive drugs. 4. Transient dizziness and drowsiness were complained by 2 patients, but subsided spontaneously with continuous treatment. 5. In view of these results, Lasix retard 30 appears to be effective and well tolerated agent for the treatment of mild to moderate hypertension, either used alone or combined with other antihypertensive drugs.
Antihypertensive Agents ; Blood Pressure ; Capsules ; Dizziness ; Female ; Furosemide ; Humans ; Hypertension ; Male ; Outpatients ; Sleep Stages

No abstract available.
Animals ; Rats*

No abstract available.
Child* ; Humans ; Immunocompromised Host ; Neutropenia ; Sepsis*

Hantavirus is a genus of the Bunyaviridae family causing two serious diseases, hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Puumala virus is a member of hantavirus originally found in Europe, and its natural reservoir is Clethrionomys glareolus. It is also associated with the hurnan disease nephropathia epidemica, a milder form of HFRS. To identify the hantaviruses in bats, bats were collected from Jeong-Sun, Won-Joo, Chung-Ju and Hwa-Cheon area in Korea, and nested RT-PCR was performed with serotype specific primer from M segment. Interestingly, Puumala virus was detected in bats (Rhinolophus ferrum-equinum) only from Won-Joo. The 327 bp nested RT-PCR product, was sequenced. The sequence database search indicates that the sequence is homologous to the published sequence of Puumala viruses. The sequence similarities were ranged from 71% to 97%. The highest sequence similarity was 97% with Puumala virus Vranicam strain, and the lowest was 71% with Puumala virus K27 isolate. Puumala virus Vranicam strain was isolated from a bank vole (Clethrionomys glareolus) in Bosnia-Hercegovina. Puumala virus K27 was isolated from human in Russia. This analysis confirms that bats (Rhinolophus ferrum-equinum) in Korea are natural reservoir of Puumala virus.
Arvicolinae ; Base Sequence ; Bunyaviridae ; Chiroptera* ; Chungcheongbuk-do ; Europe ; Hantavirus ; Hantavirus Pulmonary Syndrome ; Hemorrhagic Fever with Renal Syndrome ; Humans ; Korea* ; Puumala virus* ; Russia ; Sequence Analysis*

No abstract available.
Adolescent* ; Child* ; Humans ; Periodicals* ; Suicide*

No abstract available.
Child* ; Encephalitis* ; Female* ; Humans

No abstract available.

No abstract available.

No abstract available.
Cyclosporine ; Necrobiosis Lipoidica ; Necrobiotic Disorders